Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
American Journal of Psychoanalysis|March 20, 2009
Identity transformation in medical studentsMitchell J M Cohen, Abigail Kay, James M Youakim, et al.
Clinical Therapeutics|January 17, 2025
Assessing Experiences With Trofinetide for Rett Syndrome: Interviews With Caregivers of Participants in Clinical TrialsAmy M Barrett, Oyebimpe Olayinka-Amao, Susan Martin, et al.
The Journal of Clinical Psychiatry|August 3, 2010
Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept studyJoseph R Calabrese, Terence A Ketter, James M Youakim, et al.
Advances in Therapy|February 12, 2026
A Phase 1, Randomized, Open-Label Study to Assess the Bioequivalence of Trofinetide as a Ready-to-Use Oral Solution and Constituted Powder for Oral Solution in Healthy AdultsMona Darwish, Amy Yamamoto, Yvonne Adegbenle, et al.
The Lancet. Neurology|February 18, 2018
Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind studyClive Ballard, Carol Banister, Zunera Khan, et al.
European Journal of Drug Metabolism and Pharmacokinetics|November 8, 2024
Physiologically-Based Pharmacokinetic Modeling of Trofinetide in Moderate Renal Impairment for Phase 1 Clinical Study Dose Selection with Model ValidationMona Darwish, Thomas C Marbury, Rene Nunez, et al.
Mayo Clinic Proceedings|June 10, 2010
A phase 3, double-blind, randomized, placebo-controlled study of armodafinil for excessive sleepiness associated with jet lag disorderRussell P Rosenberg, Richard K Bogan, Jane M Tiller, et al.
The Journal of Clinical Psychiatry|September 7, 2010
Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled studyJohn M Kane, Deepak C D'Souza, Ashwin A Patkar, et al.
The Journal of Clinical Psychiatry|August 25, 2015
Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind studyMichael E Thase, James M Youakim, Aleksandar Skuban, et al.
Contemporary Clinical Trials|February 12, 2022
Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndromeJeffrey L Neul, Alan K Percy, Timothy A Benke, et al.
Pageof 3